JESSICA PELUSO: Open Payments
NPI 1548215403 · NATCHITOCHES, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,345 in 154 payments from 16 companies in 2025. Trend: 2023 $2,097 · 2024 $2,536 · 2025 $3,345
Food & beverage: $3,345
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 32 | $741 |
| GlaxoSmithKline, LLC. | 29 | $613 |
| GENZYME CORPORATION | 15 | $545 |
| Regeneron Healthcare Solutions, Inc. | 13 | $323 |
| Verona Pharma, Inc. | 11 | $243 |
| Viatris Specialty LLC | 12 | $183 |
| Actelion Pharmaceuticals US, Inc. | 10 | $159 |
| Grifols USA, LLC | 6 | $130 |
| Baxter Healthcare | 6 | $125 |
| Insmed, Inc. | 5 | $96 |
Products named: DUPIXENT, NUCALA, FASENRA, Ohtuvayre, YUPELRI, TRELEGY ELLIPTA, AIRSUPRA, TEZSPIRE.
Industry payments across LA — which companies pay providers there.
